TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20663495
Drug: Oral contraception
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraception (OC) for 6 to 8 weeks before ART
Study: 14713317
Drug: Interviewer-administered CRQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered CRQ
Study: 14713317
Drug: Self-administered CRQ
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered CRQ
Study: 9678814
Drug: 1 week
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 week co-therapy with amoxycillin (1 g b.d.) and clarithromycin (500 mg b.d.)
Study: 9678814
Drug: 2 week
Normalized name: Vimpat 2 Week Starter Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 week co-therapy with amoxycillin (1 g b.d.) and clarithromycin (500 mg b.d.)
Study: 2591463
Drug: Alfuzosin 1
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 1 mg and 5 mg
Study: 29564482
Drug: LY2140023 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2140023 (10, 40, and 160 mg)
Study: 29564482
Drug: LY2979165 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2979165 (20 and 60 mg)
Study: 26063068
Drug: Iron (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (300 mg ferrous sulfate) + 0.40 mg folate
Study: 26063068
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + 0.40 mg folate
Study: 8815481
Drug: Amikacin once
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin once daily (group A)
Study: 8815481
Drug: Amikacin thrice
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin thrice daily plus carbenicillin (group B)
Study: 8031165
Drug: UFT administration
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT administration
Study: 1444488
Drug: FT‐E administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: FT‐E administration
Study: 8630719
Drug: Terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 60 mg bid
Study: 2861767
Drug: Chlorpheniramine 4
Normalized name: chlorpheniramine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine 4 mg tid
Study: 31084483
Drug: Monthly phone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly phone calls from a mental health professional
Study: 30030699
Drug: Hazelnut and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hazelnut and cocoa spread (60 g)
Study: 30030699
Drug: Milk chocolate
Normalized name: Meritene Milk Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk chocolate (60 g)
Study: 11876700
Drug: Omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20 mg in the morning
Study: 11876700
Drug: Famotidine, 10
Normalized name: Famotidine, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine, 10 mg at bedtime
Study: 11876700
Drug: Famotidine, 10
Normalized name: Famotidine, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine, 10 mg at 05.30 h
Study: 11876700
Drug: Famotidine, 10
Normalized name: Famotidine, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine, 10 mg at bedtime and at 05.30 h
Study: 10469339
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide releasing cream (mixed with nitrite and ascorbic acid, applied three times daily)
Study: 10469339
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide releasing cream (high dose)
Study: 10469339
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide releasing cream (48 h exposure)
Study: 17164314
Drug: PTH(1-84) therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH(1-84) therapy alone
Study: 17164314
Drug: PTH(1-84) therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH(1-84) therapy with alendronate
Study: 21095149
Drug: PTH(1-84) therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH(1-84) therapy
Study: 15088780
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of laboratory passaged wild-type influenza viruses
Study: 15088780
Drug: Serum antibody
Normalized name: Pigeon serum antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum antibody
Study: 15088780
Drug: Protective factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective factors in adults with lower levels of HI antibody
Study: 15088780
Drug: Mucosal antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosal antibody measurement
Study: 11938829
Drug: Heparin (Control)
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin (Control)
Study: 30398646
Drug: Quercetin 3-glucoside
Normalized name: trans-resveratrol 3-β-glucoside
DrugBank: Polydatin (DB11263)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quercetin 3-glucoside (160 mg/d)
Study: 30398646
Drug: (−)-Epicatechin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: (−)-Epicatechin (100 mg/d)
Study: 24433317
Drug: Continuous wound
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wound infusion of a local anaesthetic
Study: 24433317
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous piritramide
Study: 19846031
Drug: Ustekinumab (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (45 mg and 90 mg)
Study: 16303729
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with benazepril 5 mg and losartan 25 mg
Study: 14750091
Drug: Losartan (greater
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (greater dose)
Study: 14750091
Drug: Benazepril (greater
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (greater dose)
Study: 11581447
Drug: Erythropoietin (Epo),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (Epo), 400 U/kg 3 times weekly
Study: 12879279
Drug: Phenylacetate (PAA)
Normalized name: phenylacetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylacetate (PAA) administered as a 30-min i.v. infusion at a dose of 1.8 g/m2
Study: 12879279
Drug: Phenylacetate (PAA)
Normalized name: phenylacetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylacetate (PAA) administered as a 30-min i.v. infusion at a dose of 2.5 g/m2
Study: 11393682
Drug: Heart rate-lowering
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate-lowering calcium antagonists (verapamil or diltiazem)
Study: 3294122
Drug: Antidiarrhoeal agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiarrhoeal agents (long acting morphine sulphate)
Study: 27144498
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy combined with conventional gel
Study: 27144498
Drug: Conventional gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional gel only (Control)
Study: 25891453
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) combination group
Study: 25891453
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine control group
Study: 19335912
Drug: Cardiac index
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac index (CI) >or= 3.0 L/min/m2
Study: 20938444
Drug: Erythromycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (3 mg Kg(‐1) infusion for 1 hour)
Study: 18708300
Drug: Oxycodone PR/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone PR/naloxone PR
Study: 25198235
Drug: Deadlift training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deadlift training (twice per week)
Study: 22267245
Drug: sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sodium bicarbonate (166 mEq/L) 3 mL/kg for 1 h before and 1 mL/kg/h for 6 h after the procedure (Group B)
Study: 22267245
Drug: sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sodium chloride 0.9% 1 mL/kg/h for at least 12h prior and after the procedure (Group A)
Study: 22267245
Drug: sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sodium bicarbonate (166 mEq/L) 3 mL/kg over 20 min before the procedure plus sodium bicarbonate orally (500 mg per 10 kg) (Group C)
Study: 17192294
Drug: rhIGF‐I administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I administered sc in doses between 60 and 120 microg/kg twice daily
Study: 14712431
Drug: 4 hours
Normalized name: PATCH, TRANSDERMAL 24 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 hours dialysis 3 times weekly
Study: 14712431
Drug: 5 hours
Normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 hours dialysis 3 times weekly
Study: 9887898
Drug: Antibiotics (Western
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (Western medicine)
Study: 7986302
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of fluvastatin once daily for 6 weeks
Study: 7986302
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of fluvastatin twice daily for 6 weeks
Study: 7986302
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of fluvastatin (both dosages)
Study: 2554766
Drug: LY171883 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY171883 (600 mg) twice daily for 6 weeks
Study: 23635604
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg) administered 1 day before and 3 days posttransplantation
Study: 16393591
Drug: L.M.X.4 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: L.M.X.4 cream (4% liposomal lidocaine)
Study: 16393591
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (2.5% lidocaine and 2.5% prilocaine)
Study: 10768435
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg of anti-digoxin Fab
Study: 8829177
Drug: Ethanol (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.07 +/- 0.003 g/dl)
Study: 1425887
Drug: Mianserin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (60 mg per day)
Study: 1425887
Drug: Imipramine (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (dose adjusted for optimal plasma concentration of 400-600 nmol.l-1)
Study: 2865152
Drug: Propranolol, Metoprolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, Metoprolol, Pindolol (lipophilic beta-blockers)
Study: 2865152
Drug: Atenolol (hydrophilic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (hydrophilic beta-blocker)
Study: 21935377
Drug: 3% SPL7013
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% SPL7013 Gel (VivaGel)
Study: 19752076
Drug: Rectal dimenhydrinate
Normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal dimenhydrinate
Study: 17179265
Drug: Lidocaine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (2 mg/kg IV for 5 min, followed by 3 mg x kg(‐1) x h(‐1) for 10 min)
Study: 11548874
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg/day for 4 weeks)
Study: 11548874
Drug: Bisoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (5 mg/day for 4 weeks)
Study: 9718471
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg single dose
Study: 9718471
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg for 7 days
Study: 30457018
Drug: Itopride HCl
Normalized name: itopride HCl
DrugBank: Itopride (DB04924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride HCl 150 mg ER pellets
Study: 30457018
Drug: Ganaton ER
Normalized name: Genaton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganaton ER 150 mg OD tablets
Study: 11523071
Drug: Test treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test treatment (three doses)
Study: 28721837
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CRT) - ≥1 serving/d (25-30 g) carbohydrates
Study: 25084499
Drug: Stigma reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stigma reduction intervention (video watched weekly for 4 weeks)
Study: 22562296
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac tromethamine 0.4% eyedrops
Study: 16986068
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of proton pump inhibitor (PPI) until symptoms resolve for NERD or until complete remission for erosive disease.
Study: 16986068
Drug: Half-dose PPI
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose PPI for maintenance treatment.
Study: 16986068
Drug: On-demand therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand therapy with half-dose PPI for NERD patients in remission.
Study: 16986068
Drug: Return to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Return to full-dose PPI for relapse of symptoms.
Study: 16986068
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with PPIs.
Study: 8735555
Drug: HDCV (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDCV (standard human diploid cell rabies vaccine)
Study: 8735555
Drug: ALVAC-RG (lowest
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-RG (lowest dose 10^3.5 TCID50)
Study: 8735555
Drug: ALVAC-RG (booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-RG (booster dose at day 180)
Study: 31233507
Drug: IDA (ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDA (ivermectin 200 μg/kg, diethylcarbamazine 6 mg/kg, albendazole 400 mg)
Study: 28128223
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline post procedure (Group A)
Study: 28128223
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous fluids post-procedure (Group B)
Study: 17173514
Drug: Acetazolamide (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (750 mg PO daily)
Study: 14505753
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of mifepristone administered on day LH+2
Study: 2908814
Drug: Fenoldopam 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam 50 mg
Study: 2908814
Drug: Fenoldopam 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam 100 mg
Study: 2908814
Drug: Fenoldopam 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam 150 mg
Study: 2908814
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg + Fenoldopam 100 mg
Study: 2908814
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg + Placebo
Study: 20019137
Drug: Total Body
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Body Weight (TBW) group (0.6 g of iodine per kilogram of TBW)
Study: 20019137
Drug: Lean Body
Normalized name: Cleanser Topical application Soap [NIVEA MEN ACTIVE CLEAN BODY WASH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean Body Weight (LBW) group (0.821 g of iodine per kilogram of LBW)
Study: 20019137
Drug: Blood Volume
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood Volume (BV) group (men, 8.6 g of iodine per liter of BV; women, 9.9 g of iodine per liter of BV)
Study: 18024370
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with idarubicin and cytarabine plus lomustine (ICL)
Study: 18024370
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with idarubicin and cytarabine (IC)
Study: 16118354
Drug: Preoperative morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative morphine (10 mg IV) and postoperative OMT
Study: 16118354
Drug: Preoperative saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative saline (control) and postoperative sham manipulative treatment
Study: 16118354
Drug: Preoperative morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative morphine (10 mg IV) and postoperative sham manipulative treatment
Study: 11383326
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d atorvastatin for 10 or more weeks
Study: 11383326
Drug: 1.68 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.68 g/d omega-3 FA (ethylesters of eicosapentaenoic and docosahexaenoic acids)
Study: 9734349
Drug: Steroid nonusers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid nonusers
Study: 3057655
Drug: Warfarin (Petersen)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (Petersen)
Study: 3057655
Drug: Warfarin (Lennon)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (Lennon)
Study: 25365753
Drug: Recombinant, live,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV)
Study: 21842613
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (specific drug not mentioned)
Study: 21842613
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose or augmentation agent
Study: 16467768
Drug: 200mg itraconazole
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg itraconazole twice daily during the first week of a 4 weeks cycle for 16 weeks
Study: 16467768
Drug: 250mg terbinafine
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg terbinafine twice daily during the first week of a 4 weeks cycle for 16 weeks
Study: 6687578
Drug: Agiolax (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agiolax (15 mg senna glucosides)
Study: 6687578
Drug: Lunelax comp.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lunelax comp. (25 mg senna glucoside A + B)
Study: 25961147
Drug: Social Behavior
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Behavior and Network Therapy (SBNT)
Study: 27780504
Drug: PFNA combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFNA combined with zoledronic acid injection (5 mg/100 ml via intravenous drip)
Study: 27780504
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (PFNA with 600 mg of Caltrate D and 0.25 mg of alpha ossification alcohol)
Study: 18853704
Drug: Ramelteon 1
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon 1 mg once daily for 4 days
Study: 18853704
Drug: Ramelteon 2
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon 2 mg once daily for 4 days
Study: 18853704
Drug: Ramelteon 4
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon 4 mg once daily for 4 days
Study: 18853704
Drug: Ramelteon 8
Normalized name: ramelteon 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon 8 mg once daily for 4 days
Study: 14619332
Drug: Omalizumab, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab, 300 mg, administered subcutaneously every 4 weeks (three injections) for IgE levels < or = 150 IU/mL and every 3 weeks (four injections) for IgE levels > 150 IU/mL.
Study: 1747004
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of fluconazole daily for 12 weeks
Study: 1747004
Drug: No fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No fluconazole treatment
Study: 6341070
Drug: Diphenylhydantoin (PHT,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenylhydantoin (PHT, 200 mg/day)
Study: 6341070
Drug: Diphenylhydantoin (PHT,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenylhydantoin (PHT, 300 mg/day)
Study: 6341070
Drug: Carbamazepine (CBZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (CBZ, 600 mg/day)
Study: 6341070
Drug: Carbamazepine (CBZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (CBZ, 800 mg/day)
Study: 6608483
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 (50,000 IU p.o. two to three times weekly)
Study: 6608483
Drug: 25-OH-D (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-OH-D (20 to 50 mg p.o. daily as required)
Study: 6608483
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no supplemental vitamin D treatment)
Study: 28139626
Drug: Cerebrolysin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin 20 ml per 200 ml of 0.9% NaCl solution, 1 time per day for 10 days (G1)
Study: 28139626
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml 0.9% NaCl solution (G2)
Study: 24925592
Drug: Insulin-requiring gestational
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-requiring gestational diabetes